Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide prognostic and therapeutic implications

Cancer

Volumn 83, Issue 5, 1998, Pages 936-947

  Karlsson, Ylva A ^a   Malmström, Per O ^b   Hatschek, Thomas ^c   Fornander, Tommy G ^d   Söderberg, Martin ^e   Bengtsson, Nils Olof ^f   Jansson, Tomas E ^a   Sjöberg, Sara M ^d   Bergh, Jonas C ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast carcinoma; Chemotherapy; Dose intensity; Inflammatory; Locally advanced; Multimodality treatment; Neoadjuvant; Preoperative

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADVANCED CANCER; ALOPECIA; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PROTOCOL; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032168519     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<936::AID-CNCR20>3.0.CO;2-V     Document Type: Article

References (38)

1. Lippman M, Sorace R, Bagley C, Danforth D Jr., Lichter A, Wesley M. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986;1:153-9.
2. Valero V, Buzdar A, Hortobagyi G. Locally advanced breast cancer. Oncologist 1996;1:8-17.
3. International Union Against Cancer. Hermanek P, Sobin L, editors.TNM classification of malignant tumors, 4th edition. Berlin: Springer-Verlag, 1987.
4. Hortobagyi G, Buzdar A. Locally advanced breast cancer: a review including the M. D. Anderson experience. In: Ragaz J, Ariel I, editors. High-risk breast cancer. Berlin: Springer-Verlag, 1991:382-415.
5. Jaiyesimi I, Buzdar A, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
6. Palangie T, Mosseri V, Mihura J, Campana F, Beuzeboc P, Dorval T, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994;30A: 921-7.
7. Attia-Sobol J, Ferrière J-P, Curé H, Kwiatkowski F, Achard J-L, Verrelle P, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 1993;29A:1081-8
8. Hortobagyi G, Singletary S, McNeese M. Treatment of locally advanced and inflammatory breast cancer. In: Harris J, Lippman M, Marrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996; 585-99.
9. Semiglazov V, Topuzov E, Bavli J, Moiseyenko V, Ivanova O, Seleznev I, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994;5:591-5.
10. Perez C, Graham M, Taylor M, Levy J, Mortimer J, Philpott G, et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994;74(Suppl 1):453-65.
11. Graham M, Perez C, Kuske R, Garcia D, Fineberg B. Locally advanced (noninflammatory) carcinoma of the breast: results and comparison of various treatment modalities. Int J Radiat Oncol Biol Phys 1991;21:311-8.
12. Kirk J, Gray W, Watson E. Cumulative radiation effect. Part VI. Simple nomographic and tabular methods for the solution of practical problems. J Clin Radiol 1977;28:29-74.
13. Haagensen C, Stout A. Carcinoma of the breast. II. Criteria of operability. Ann Surg 1943;118:859-70,1032-51.
14. Cox D. Regression models and life-tables (with discussion). J R Stat Soc 1972;34:187-220.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Sta Assoc 1958;53:457-81.
16. Hryniuk W, Levine M. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-70.
17. van der Wall E, Rutgers E, Holtkamp M, Baars J, Schornagel J, Peterse J, et al. Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br J Cancer 1996;73:1080-5.
18. Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bougnoux A, Lemarié E, et al. Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys 1993;26:37-42.
19. Singletary S, McNeese M, Hortobagyi G. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69:2849-53.
20. Hortobagyi G, Blumenschein G, Spanos W, Montague E, Buzdar A, Yap H-Y, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8.
21. Perez C, Fields J, Fracasso P, Philpott G, Soares R Jr., Taylor M, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 1994;74(Suppl 1):466-76.
22. A'Hern R, Ebbs S, Baum M. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988;57:615-8.
23. Mouridsen H, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, et al. Current status of epirubicin (farmorubicin) in the treatment of solid tumours. Acta Oncol 1990;29:257-85.
24. Hryniuk W, Bush H. The importance of dose-intensity in chemotherapy for metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
25. Habeshaw T, Jones P, Stewart S, Kaye S, Soukop M, Symonds R, et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991;9:295-304.
26. Armstrong D, Fetting J, Davidson N, Gordon G, Huelskamp A, Abeloff M. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993;28:277-84.
27. Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-71.
28. Focan C, Andrien J, Closon M, Dicato M, Driesschaert P, Focan-Henrard D, et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 1993; 11:1253-63.
29. Bastholt L, Dalmark M, Gjedde S, Pfeiffer P, Pedersen D, Sandberg E, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group. J Clin Oncol 1996;14:1146-55.
30. The French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991;9:305-12.
31. 2) in the FEC regimen significantly increases response rates: an international randomised phase III study in metastatic breast cancer. Ann Oncol 1997;8:155-62.
32. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
33. Antman K, Eder J, Elias A, Ayash L, Shea T, Weissman L, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 1990;17:33-8.
34. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Heller L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993; 11:467-73.
35. Saarto T, Blomqvist C, Tiusanen K, Gröhn P, Rissanen P, Elomaa I. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen: eight year follow-up results of randomized trial. Eur J Surg Oncol 1995; 21:146-50.
36. Palm Sjövall M, Malmström P. Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. Acta Oncol 1997;36:207-12.
37. Paridaens R, Heuson J, Julien J, Veyret C, van Zyl J, Klijn J, et al. Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. J Clin Oncol 1993;11:1723-8.
38. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients: an update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992;28:673-80.